Altınok Pelin, Tekçe Ertuğrul, Kızıltan Huriye Şenay, Gücin Zühal, Mayadağlı Alpaslan
Department of Radiation Oncology, Ümraniye Training and Research Hospital, University of Health Sciences, İstanbul, Turkey.
Department of Radiation Oncology, Bezmialem Vakıf University Faculty of Medicine, İstanbul, Turkey.
Eur J Breast Health. 2023 Oct 1;19(4):287-296. doi: 10.4274/ejbh.galenos.2023.2023-5-4. eCollection 2023 Oct.
Breast-conserving surgery (BCS) followed by radiotherapy (RT) is the standard treatment for early-stage breast cancer. The use of an additional RT dose (boost) to the tumour bed improves local control but may worsen quality of life (QOL) and cosmetic results. Multifocal/multicentric tumours (MMTs) pose a challenge as they require larger boost volumes. This study investigated the impact of RT volumes on late-term cosmetic outcomes and QOL in patients with unifocal and MMTs who underwent adjuvant RT after BCS.
Retrospective data of 367 patients who underwent BCS between 2012 and 2014 were reviewed. A cohort of 121 patients with at least six months of completed RT were prospectively included in the study. Cosmetic results were evaluated using a modified scoring system, and QOL was assessed using The European Cancer Treatment and Organization Committee tools.
The results showed that the inclusion of regional lymphatics in the RT treatment field significantly affected QOL, particularly in terms of role functioning and social functioning. Higher boost volume ratios were associated with increased pain-related symptoms. However, the presence of MMTs did not significantly affect cosmetic outcomes compared to unifocal tumours.
The size of the boost and inclusion of regional lymphatics in RT significantly impact QOL in patients undergoing BCS. Tumour foci number does not affect cosmetic outcomes. These findings emphasize the need for careful consideration of RT volumes to minimize long-term adverse effects on QOL. Future prospective studies should evaluate early side effects and baseline QOL scores to provide a comprehensive assessment.
保乳手术(BCS)联合放疗(RT)是早期乳腺癌的标准治疗方法。对瘤床增加放疗剂量(追加放疗)可提高局部控制率,但可能会恶化生活质量(QOL)和美容效果。多灶性/多中心性肿瘤(MMTs)是一项挑战,因为它们需要更大的追加放疗体积。本研究调查了放疗体积对保乳手术后接受辅助放疗的单灶性和多灶性肿瘤患者晚期美容效果和生活质量的影响。
回顾了2012年至2014年间接受保乳手术的367例患者的回顾性数据。前瞻性纳入了121例至少完成放疗6个月的患者。使用改良评分系统评估美容效果,使用欧洲癌症治疗与组织委员会工具评估生活质量。
结果表明,放疗野中纳入区域淋巴结显著影响生活质量,特别是在角色功能和社会功能方面。更高的追加放疗体积比与疼痛相关症状增加有关。然而,与单灶性肿瘤相比,多灶性肿瘤的存在对美容效果没有显著影响。
追加放疗的大小和放疗野中纳入区域淋巴结对接受保乳手术的患者的生活质量有显著影响。肿瘤灶数量不影响美容效果。这些发现强调需要仔细考虑放疗体积,以尽量减少对生活质量的长期不良影响。未来的前瞻性研究应评估早期副作用和基线生活质量评分,以提供全面评估。